Swift Biosciences, Inc. today announced the launch of an early access program for Accel-NGS™ Amplicon Panels for use with Illumina Next Generati on Sequencing (NGS) systems. The assays are compatible with FFPE and circulating cell free DNA from 10 ng of genomic DNA. The underlying technology enables hundreds of primer pa irs to be amplified in a single tube. The panels can be used to target either contiguous cove rage of a single gene, multiple loci throughout the genome, or a combination of both.
The initial product is a comprehensive TP53 panel, a clinically important tumor suppressor gene.* This panel covers all coding exons of TP53 in a sin gle tube format. Another panel under development based on this technology targets over 2 00 clinically relevant oncology mutations. Swift Biosciences will also soon offer custom panel design capability.
“We are excited about offering an early access prog ram for translational ...
